Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BARD C R INC /NJ/BCR · Entity 170698 | Director | December 29, 2017 | January 03, 2018 |
| CENTENE CORPCNC · Entity 3133 | Director | December 31, 2021 | January 05, 2022 |
| HEALTHPEAK PROPERTIES, INC.DOC · Entity 3364 | Director | May 28, 2025 | May 28, 2025 |
| Scilex Holding CoSCLX · Entity 7345 | Director | January 17, 2023 | January 17, 2023 |
| TYME TECHNOLOGIES, INC.TYME · Entity 123718 | Director | August 22, 2019 | August 27, 2019 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | December 23, 2025 | December 29, 2025 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director | July 22, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BARD C R INC /NJ/
Report date December 29, 2017 · Filed January 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 1
1 source rowRow 1 · 2017-12-29 · Disposition to issuer · Disposed 6,293 · Balance 0 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.76 · Expires 2018-07-09 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-12-29 · Disposition to issuer · Disposed 1,200 · Balance 0 F2: Award/Grant pursuant to the 2005 Directors' Stock Award Plan, as amended and restated. F3: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.70 · Expires 2019-12-09 | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-12-29 · Disposition to issuer · Disposed 1,200 · Balance 0 F2: Award/Grant pursuant to the 2005 Directors' Stock Award Plan, as amended and restated. F3: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,028.46 |
Reported balance
After 2017-12-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-12-29 · Grant · Acquired 37.65 · Balance 8,028.46 F4: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees. F5: Conversion is 1 for 1. F6: Phantom stock units are settled in cash upon termination of service as director. F7: Includes 50.46 units for dividend credits. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-12-29 · Disposition to issuer · Disposed 8,028.46 · Balance 0 F4: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees. F5: Conversion is 1 for 1. F8: These units, which are 100% vested, were paid out in cash in accordance with the Merger Agreement. |
| Share Equivalent UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-12-29 · Disposition to issuer · Disposed 8,541 · Balance 0 F9: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F10: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration").
F2: Award/Grant pursuant to the 2005 Directors' Stock Award Plan, as amended and restated.
F3: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
F4: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees.
F5: Conversion is 1 for 1.
F6: Phantom stock units are settled in cash upon termination of service as director.
F7: Includes 50.46 units for dividend credits.
F8: These units, which are 100% vested, were paid out in cash in accordance with the Merger Agreement.
F9: Units granted under the Company's Stock Equivalent Plan for Outside Directors.
F10: These units, which are 100% vested, were assumed by BD at the effective time of the Merger.
CENTENE CORP
Report date December 31, 2021 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 227,334.239 |
Reported balance
After 2021-12-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-12-31 · Grant · Acquired 450.241 · Balance 227,334.239 F1: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 26,896 |
Reported balance
Holding disclosure · report date 2021-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 26,896 F2: Shares held by a family investment LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 74,000 |
Reported balance
Holding disclosure · report date 2021-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 74,000 F3: Shares held by the Sue Ann Thompson Endowment Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 60,000 |
Reported balance
Holding disclosure · report date 2021-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 60,000 F4: Shares held by the Tommy G Thompson Family Endowment Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements.
F2: Shares held by a family investment LLC.
F3: Shares held by the Sue Ann Thompson Endowment Trust.
F4: Shares held by the Tommy G Thompson Family Endowment Trust.
HEALTHPEAK PROPERTIES, INC.
Report date May 28, 2025 · Filed May 28, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 144,290 |
Reported balance
After 2025-05-28 transaction · row 1
1 source rowRow 1 · 2025-05-28 · Purchase · Acquired 5,777 · Balance 144,290 |
Scilex Holding Co
Report date January 17, 2023 · Filed January 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2033-01-17 | Direct | 250,000 |
Reported balance
After 2023-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-17 · Grant · Acquired 250,000 · Balance 250,000 F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.
TYME TECHNOLOGIES, INC.
Report date August 22, 2019 · Filed August 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option - right to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2029-08-21 | Direct | 50,000 |
Reported balance
After 2019-08-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-08-22 · Grant · Acquired 50,000 · Balance 50,000 F1: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments.
TherapeuticsMD, Inc.
Report date December 23, 2025 · Filed December 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,179 |
Reported balance
After 2025-12-23 transaction · row 1
1 source rowRow 1 · 2025-12-23 · Purchase · Acquired 8,400 · Balance 23,179 |
| Common StockSEC Table I · non-derivative | IndirectThompson Family Holdings, LLC, owned by Mr. Thompson. | 21 |
Reported balance
Holding disclosure · report date 2025-12-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 21 |
| Common StockSEC Table I · non-derivative | IndirectThompson Family Investments, LLC, owned by Thompson Family Holdings, LLC, owned by Mr. Thompson | 14,312 |
Reported balance
Holding disclosure · report date 2025-12-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 14,312 |
UNITED THERAPEUTICS Corp
Report date July 22, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 380 |
Reported balance
After 2026-07-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-22 · Grant · Acquired 380 · Balance 380 F2: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3: Annual non-employee director award. F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F5: Not applicable as restricted stock units do not have an expiration date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $527.07 · Expires 2033-07-22 | Direct | 1,190 |
Reported balance
After 2026-07-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-22 · Grant · Acquired 1,190 · Balance 1,190 F3: Annual non-employee director award. F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. |
| Common StockSEC Table I · non-derivative | Direct | 8,480 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 8,480 F1: Includes 880 shares of common stock issued on July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 8,200 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,200 |
| Common StockSEC Table I · non-derivative | Indirectby Family LLC | 5,800 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 880 shares of common stock issued on July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares.
F2: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
F3: Annual non-employee director award.
F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
F5: Not applicable as restricted stock units do not have an expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Physicians Realty Trust
Report date March 01, 2024 · Filed March 01, 2024
Section 16 reporting ended · disclosed 2024-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-03-01 · Exercise / conversion · Acquired 4,582 · Balance 156,830 F1: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Represents vesting of the time-based restricted stock units on March 1, 2024 pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated October 29, 2023 among the Issuer, Physicians Realty L.P., Healthpeak Properties, Inc. ("Healthpeak"), DOC DR Holdco, LLC and DOC DR LLC. The Issuer merged with and into DOC DR Holdco, LLC on March 1, 2024. Row 2 · 2024-03-01 · Exercise / conversion · Acquired 10,205 · Balance 167,035 F1: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Represents vesting of the time-based restricted stock units on March 1, 2024 pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated October 29, 2023 among the Issuer, Physicians Realty L.P., Healthpeak Properties, Inc. ("Healthpeak"), DOC DR Holdco, LLC and DOC DR LLC. The Issuer merged with and into DOC DR Holdco, LLC on March 1, 2024. Row 3 · 2024-03-01 · Disposition to issuer · Disposed 167,035 · Balance 0 F2: Represents securities disposed of pursuant to the terms of the the Merger Agreement and each issued and outstanding common shares of the Issuer, held by the reporting person was automatically converted into the right to receive 0.674 of a share of Healthpeak common stock, subject to any adjustment, without interest. |
| Common shares, $0.01 par valueSEC Table I · non-derivative | IndirectRepresents shares held by Thompson Family Charitable Foundation | 0 |
Reported balance
After 2024-03-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-03-01 · Disposition to issuer · Disposed 25,635 · Balance 0 F2: Represents securities disposed of pursuant to the terms of the the Merger Agreement and each issued and outstanding common shares of the Issuer, held by the reporting person was automatically converted into the right to receive 0.674 of a share of Healthpeak common stock, subject to any adjustment, without interest. |
| 2022 Restricted Share Unit GrantSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-01 · Exercise / conversion · Disposed 4,582 · Balance 0 F3: On March 1, 2022, the Reporting Person was granted 9,164 restricted stock units, which vest in two equal installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement. |
| 2023 Restricted Share Unit GrantSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-01 · Exercise / conversion · Disposed 10,205 · Balance 0 F4: On March 1, 2023, the Reporting Person was granted 10,205 restricted stock units, which vest in two equal installments on March 1, 2024 and March 1, 2025, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Represents vesting of the time-based restricted stock units on March 1, 2024 pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated October 29, 2023 among the Issuer, Physicians Realty L.P., Healthpeak Properties, Inc. ("Healthpeak"), DOC DR Holdco, LLC and DOC DR LLC. The Issuer merged with and into DOC DR Holdco, LLC on March 1, 2024.
F2: Represents securities disposed of pursuant to the terms of the the Merger Agreement and each issued and outstanding common shares of the Issuer, held by the reporting person was automatically converted into the right to receive 0.674 of a share of Healthpeak common stock, subject to any adjustment, without interest.
F3: On March 1, 2022, the Reporting Person was granted 9,164 restricted stock units, which vest in two equal installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.
F4: On March 1, 2023, the Reporting Person was granted 10,205 restricted stock units, which vest in two equal installments on March 1, 2024 and March 1, 2025, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2022 Filed Jul 8, 2022 21:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 2,490 | $0.00 Strike: $240.20 | $0.00 |
DisclosureSEC source: 0001415889-22-007601 · form4-07082022_020744.xml · derivative · entry 6 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,980 Underlying: Common Stock · 2,490 shares Expires 2032-07-07 F4 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 880 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007601 · form4-07082022_020744.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880 Underlying: Common Stock · 880 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F5 · derivative.exercise_date: The reporting person has elected to defer receipt of the shares upon conversion of t his award until on or about July 7, 2024. F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| May 26, 2022 Filed May 26, 2022 23:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 2,200 | $0.00 Strike: $48.11 | $0.00 |
DisclosureSEC source: 0001415889-22-005733 · form4-05262022_040527.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,200 shares Expires 2022-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 26, 2022 Filed May 26, 2022 23:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 2,200 | $224.78 | $494,516.00 |
DisclosureSEC source: 0001415889-22-005733 · form4-05262022_040527.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 26, 2022 Filed May 26, 2022 23:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 2,200 | $48.11 | $105,842.00 |
DisclosureSEC source: 0001415889-22-005733 · form4-05262022_040527.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,500 | $0.00 Strike: $48.11 | $0.00 |
DisclosureSEC source: 0001415889-22-003475 · form4-03302022_040303.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 1,500 shares Expires 2022-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,500 | $178.46 | $267,690.00 |
DisclosureSEC source: 0001415889-22-003475 · form4-03302022_040303.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,500 | $48.11 | $72,165.00 |
DisclosureSEC source: 0001415889-22-003475 · form4-03302022_040303.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,509 | $0.00 Strike: $48.11 | $0.00 |
DisclosureSEC source: 0001415889-22-003191 · form4-03182022_010337.xml · derivative · entry 8 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 Underlying: Common Stock · 1,509 shares Expires 2022-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,509 | $184.49 | $278,395.41 |
DisclosureSEC source: 0001415889-22-003191 · form4-03182022_010337.xml · nonDerivative · entry 4 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,509 | $48.11 | $72,597.99 |
DisclosureSEC source: 0001415889-22-003191 · form4-03182022_010337.xml · nonDerivative · entry 3 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,500 | $0.00 Strike: $48.11 | $0.00 |
DisclosureSEC source: 0001415889-22-003191 · form4-03182022_010337.xml · derivative · entry 7 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,209 Underlying: Common Stock · 1,500 shares Expires 2022-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,500 | $182.55 | $273,825.00 |
DisclosureSEC source: 0001415889-22-003191 · form4-03182022_010337.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,500 | $48.11 | $72,165.00 |
DisclosureSEC source: 0001415889-22-003191 · form4-03182022_010337.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,500 | $0.00 Strike: $48.11 | $0.00 |
DisclosureSEC source: 0001415889-22-003050 · form4-03162022_040302.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,709 Underlying: Common Stock · 1,500 shares Expires 2022-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,500 | $178.82 | $268,230.00 |
DisclosureSEC source: 0001415889-22-003050 · form4-03162022_040302.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,500 | $48.11 | $72,165.00 |
DisclosureSEC source: 0001415889-22-003050 · form4-03162022_040302.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $48.11 | $0.00 |
DisclosureSEC source: 0001415889-22-002893 · form4-03112022_040301.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,209 Underlying: Common Stock · 1,000 shares Expires 2022-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Share tracking awards are non-dilutive, cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $167.78 | $167,780.00 |
DisclosureSEC source: 0001415889-22-002893 · form4-03112022_040301.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $48.11 | $48,110.00 |
DisclosureSEC source: 0001415889-22-002893 · form4-03112022_040301.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,500 | $0.00 Strike: $48.11 | $0.00 |
DisclosureSEC source: 0001415889-22-002547 · form4-03042022_010336.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,209 Underlying: Common Stock · 1,500 shares Expires 2022-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,500 | $174.96 | $262,440.00 |
DisclosureSEC source: 0001415889-22-002547 · form4-03042022_010336.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,500 | $48.11 | $72,165.00 |
DisclosureSEC source: 0001415889-22-002547 · form4-03042022_010336.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:10 UTC | Physicians Realty Trust DOC · Entity 93614 | Exercise / conversion2020 Restricted Share Unit Grant · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · derivative · entry 6 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares, $0.01 par value · 3,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F5 · derivative.exercise_date: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F5 · derivative.expiration_date: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:10 UTC | Physicians Realty Trust DOC · Entity 93614 | Exercise / conversionCommon shares, $0.01 par value | 3,886 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:10 UTC | Physicians Realty Trust DOC · Entity 93614 | Grant2022 Restricted Share Unit Grant · Derivative | 9,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,164 Underlying: Common shares, $0.01 par value · 9,164 shares Expires not disclosed F4 · derivative.exercise_price: March 1, 2022 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F4 · derivative.exercise_date: March 1, 2022 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F4 · derivative.expiration_date: March 1, 2022 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:10 UTC | Physicians Realty Trust DOC · Entity 93614 | Exercise / conversion2021 Restricted Share Unit Grant · Derivative | 4,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · derivative · entry 4 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,358 Underlying: Common shares, $0.01 par value · 4,358 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: March 1, 2021, the Reporting Person was granted 8,716 restricted stock units, which vest in two equal installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F3 · derivative.exercise_date: March 1, 2021, the Reporting Person was granted 8,716 restricted stock units, which vest in two equal installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F3 · derivative.expiration_date: March 1, 2021, the Reporting Person was granted 8,716 restricted stock units, which vest in two equal installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:10 UTC | Physicians Realty Trust DOC · Entity 93614 | Exercise / conversionCommon shares, $0.01 par value | 4,358 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F2 · balance_after: Includes 3,542 shares acquired under the Dividend Reinvestment and Share Purchase Plan. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 02:01 UTC | CENTENE CORP CNC · Entity 3133 | GrantCommon Stock | 450.241 | $0.00 | $0.00 |
DisclosureSEC source: 0001071739-22-000009 · wf-form4_164134805640075.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,334.239 F1 · balance_after: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 22:59 UTC | CENTENE CORP CNC · Entity 3133 | GrantCommon Stock | 523.795 | $66.82 | $34,999.98 |
DisclosureSEC source: 0001071739-21-000213 · wf-form4_163338832956218.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,883.998 F1 · balance_after: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 10:47 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 11,000 | $0.87 | $9,570.00 |
DisclosureSEC source: 0001387131-21-008639 · ownership.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 715,600 F1 · ownership.nature: The reported securities are owned by Thompson Family Investments, LLC, an entity solely owned by Thompson Family Holdings, LLC, an entity solely owned by Mr. Thompson. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:29 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 145,296 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-008435 · ownership.xml · derivative · entry 4 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,596 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 10, 2021, the reporting person received 145,296 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F4 · shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. F5 · derivative.exercise_date: The RSUs fully vested on June 18, 2021. F5 · derivative.expiration_date: The RSUs fully vested on June 18, 2021. F1 · derivative.underlying_shares: On August 10, 2021, the reporting person received 145,296 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F4 · derivative.underlying_shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:29 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 145,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-008435 · ownership.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 10, 2021, the reporting person received 145,296 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 21:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 1,080 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021767 · form4.xml · derivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080 Underlying: Common Stock · 1,080 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders. F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F2 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 21:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 3,230 | $183.98 Strike: $183.98 | $594,255.40 |
DisclosureSEC source: 0001127602-21-021767 · form4.xml · derivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,230 Underlying: Common Stock · 3,230 shares Expires 2031-07-08 F1 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders. F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:56 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 148,760 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-007125 · ownership.xml · derivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,760 Underlying: Common Stock · 148,760 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 23:03 UTC | CENTENE CORP CNC · Entity 3133 | GrantCommon Stock | 510.874 | $68.51 | $34,999.98 |
DisclosureSEC source: 0001071739-21-000173 · wf-form4_162526699702265.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,360.203 F1 · balance_after: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements. Read SEC document |
| June 26, 2021 Filed Jun 29, 2021 20:39 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 1,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020805 · form4.xml · derivative · entry 4 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2021 Filed Jun 29, 2021 20:39 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020805 · form4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 26, 2021. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| May 14, 2021 Filed May 18, 2021 10:55 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 5,000 | $1.06 | $5,300.00 |
DisclosureSEC source: 0001387131-21-005770 · ownership.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 704,600 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $1.055 to $1.06 for an average weighted sale price of $1.06. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reported securities are owned by Thompson Family Investments, LLC, an entity solely owned by Thompson Family Holdings, LLC, an entity solely owned by Mr. Thompson. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 00:34 UTC | CENTENE CORP CNC · Entity 3133 | GrantCommon Stock | 3,300 | $66.00 | $217,800.00 |
DisclosureSEC source: 0001071739-21-000115 · wf-form4_161965643446136.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,849.329 F1 · balance_after: Ownership includes 3,300 shares of restricted stock vesting on the date of the April 2022 Annual Meeting of Stockholders, subject to meeting Board of Director meeting attendance conditions. Read SEC document |
| March 31, 2021 Filed Apr 3, 2021 00:09 UTC | CENTENE CORP CNC · Entity 3133 | GrantCommon Stock | 565.245 | $61.92 | $34,999.97 |
DisclosureSEC source: 0001071739-21-000079 · wf-form4_161740847006609.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,549.329 F1 · balance_after: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 12,350 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-21-010232 · form4.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,350 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. These awards were granted June 29, 2011 and were set to expire June 29, 2021. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 12,350 | $159.68 | $1,972,048.00 |
DisclosureSEC source: 0001127602-21-010232 · form4.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,840 F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. These awards were granted June 29, 2011 and were set to expire June 29, 2021. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 12,350 | $54.77 | $676,409.50 |
DisclosureSEC source: 0001127602-21-010232 · form4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. These awards were granted June 29, 2011 and were set to expire June 29, 2021. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:29 UTC | Physicians Realty Trust DOC · Entity 93614 | Exercise / conversion2020 Restricted Share Unit Grant · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · derivative · entry 6 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,886 Underlying: Common shares, $0.01 par value · 3,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F5 · derivative.exercise_date: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F5 · derivative.expiration_date: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:29 UTC | Physicians Realty Trust DOC · Entity 93614 | Exercise / conversionCommon shares, $0.01 par value | 3,886 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:29 UTC | Physicians Realty Trust DOC · Entity 93614 | Grant2021 Restricted Share Unit Grant · Derivative | 8,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · derivative · entry 5 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,716 Underlying: Common shares, $0.01 par value · 8,716 shares Expires not disclosed F4 · derivative.exercise_price: March 1, 2021 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F4 · derivative.exercise_date: March 1, 2021 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F4 · derivative.expiration_date: March 1, 2021 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:29 UTC | Physicians Realty Trust DOC · Entity 93614 | Exercise / conversion2019 Restricted Share Unit Grant · Derivative | 4,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · derivative · entry 4 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares, $0.01 par value · 4,192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: March 1, 2019, the Reporting Person was granted 8,385 restricted stock units, which vest in two equal installments on March 1, 2020 and March 1, 2021, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F3 · derivative.exercise_date: March 1, 2019, the Reporting Person was granted 8,385 restricted stock units, which vest in two equal installments on March 1, 2020 and March 1, 2021, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F3 · derivative.expiration_date: March 1, 2019, the Reporting Person was granted 8,385 restricted stock units, which vest in two equal installments on March 1, 2020 and March 1, 2021, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:29 UTC | Physicians Realty Trust DOC · Entity 93614 | Exercise / conversionCommon shares, $0.01 par value | 4,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. F2 · balance_after: Includes 3,259 shares acquired under the Dividend Reinvestment and Share Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.